Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 1
2015 1
2017 1
2019 2
2020 1
2021 1
2022 1
2023 2
2024 2
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. Nassiri F, et al. Nat Med. 2023 Jun;29(6):1370-1378. doi: 10.1038/s41591-023-02347-y. Epub 2023 May 15. Nat Med. 2023. PMID: 37188783 Free PMC article. Clinical Trial.
Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this multicenter phase 1/2 study we evaluated the combination of intratumoral deli …
Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatmen …
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
Omuro A. Omuro A. Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):266-269. doi: 10.1590/0004-282X-ANP-2022-S129. Arq Neuropsiquiatr. 2022. PMID: 35976319 Free PMC article. Review.
Phase 1 studies of nivolumab with and without ipilimumab, as well as pembrolizumab, showed no new safety concerns in brain tumors, and no neurotoxicity. However, randomized phase 3 trials of nivolumab showed no survival improvements over bevacizumab in recurr …
Phase 1 studies of nivolumab with and without ipilimumab, as well as pembrolizumab, showed no new safety concerns in brain tum …
First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors.
Yap TA, Rixe O, Baldini C, Brown-Glaberman U, Efuni S, Hong DS, Massard C, Muzaffar J, Varga A, Yilmaz E, Ikawa Y, Shiue LH, Liu Y, Hruska MW, Zhao H, Tokunaga A, Sahebjam S. Yap TA, et al. Cancer. 2025 Jul 1;131(13):e35939. doi: 10.1002/cncr.35939. Cancer. 2025. PMID: 40536766 Free PMC article. Clinical Trial.
KHK2455 + mogamulizumab demonstrated enhanced antitumor activity in preclinical studies, which led to a first-in-human, two-part, multicenter, open-label, phase 1, dose-escalation, cohort-expansion trial (ClinicalTrials.gov identifier NCT02867007) evaluating the saf …
KHK2455 + mogamulizumab demonstrated enhanced antitumor activity in preclinical studies, which led to a first-in-human, two-part, multicente …
Phase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomas.
Sahebjam S, Raval RR, Forsyth PA, Enderling H, Tran ND, Arrington JA, Macaulay R, Perlow HK, Palmer JD, Ghose J, Rajappa P, Giglio P, Li Z, Etame AB, Mokhtari S, Cruz-Chamorro RJ, Bhandari M, Thapa R, Robinson TJ, Chen DT, Yu HM. Sahebjam S, et al. Neurooncol Adv. 2025 Feb 8;7(1):vdaf033. doi: 10.1093/noajnl/vdaf033. eCollection 2025 Jan-Dec. Neurooncol Adv. 2025. PMID: 40134851 Free PMC article.
This subsequent trial investigated the dual blockade of CTLA4 and PD-1 in combination with HFSRT and bevacizumab. METHODS: This phase I study enrolled eligible patients with bevacizumab-naive recurrent glioblastoma or anaplastic astrocytoma. Participants rece …
This subsequent trial investigated the dual blockade of CTLA4 and PD-1 in combination with HFSRT and bevacizumab. METHODS: This phase …
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial.
Giordano FA, Layer JP, Turiello R, Friker LL, Mirallas O, Pregler BEF, Potthoff AL, Zeyen T, Weller J, Sperk E, Sahm K, Oster C, Kebir S, Hambsch P, Schäfer N, Kadzik S, Renovanz M, Pietsch T, Bisdas S, Sepúlveda-Sánchez JM, Gómez-Puerto D, Vieito M, Platten M, Gkika E, Grauer OM, Tabatabai G, Schneider M, Glas M, Seidel C, Herrlinger U, Hölzel M. Giordano FA, et al. Nat Commun. 2026 Apr 8;17(1):3405. doi: 10.1038/s41467-026-71362-7. Nat Commun. 2026. PMID: 41951573 Free PMC article. Clinical Trial.
Rapid vascular recovery is a key feature preceding glioblastoma (GBM) recurrence after radiotherapy (RT). We performed spatial expression analyses, providing a rationale for dual inhibition of two non-redundant, spatially distinct acting factors, CXCL12 and VEGF. Subsequen …
Rapid vascular recovery is a key feature preceding glioblastoma (GBM) recurrence after radiotherapy (RT). We performed spatial expres …
Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma.
Brenner AJ, Floyd J, Fichtel L, Michalek J, Kanakia KP, Huang S, Reardon D, Wen PY, Lee EQ. Brenner AJ, et al. Sci Rep. 2021 Jan 27;11(1):2306. doi: 10.1038/s41598-021-81841-0. Sci Rep. 2021. PMID: 33504881 Free PMC article. Clinical Trial.
Evofosfamide (Evo or TH302) is a hypoxia-activated prodrug which is reduced leading to the release of alkylating agent bromo-isophosphoramide mustard, which has shown safety and signals of efficacy in a prior phase 1 study in recurrent glioblastoma. We perfor …
Evofosfamide (Evo or TH302) is a hypoxia-activated prodrug which is reduced leading to the release of alkylating agent bromo-isophosphoramid …
Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design.
Sener U, Islam M, Webb M, Kizilbash SH. Sener U, et al. Neurooncol Adv. 2024 Mar 15;6(1):vdae039. doi: 10.1093/noajnl/vdae039. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38596714 Free PMC article.
We also reviewed the literature pertaining to bevacizumab withdrawal. RESULTS: Two hundred and ninety-seven studies for patients with recurrent glioma were reviewed. Most were phase 1 (n = 145, 49%), non-randomized (n = 257, 87%), evaluated a dr …
We also reviewed the literature pertaining to bevacizumab withdrawal. RESULTS: Two hundred and ninety-seven studies for patients with …
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D. Galanis E, et al. Cancer. 2019 Nov 1;125(21):3790-3800. doi: 10.1002/cncr.32340. Epub 2019 Jul 10. Cancer. 2019. PMID: 31290996 Free PMC article. Clinical Trial.
BACKGROUND: Src signaling is markedly upregulated in patients with invasive glioblastoma (GBM) after the administration of bevacizumab. The Src family kinase inhibitor dasatinib has been found to effectively block bevacizumab-induced glioma invasion in precli …
BACKGROUND: Src signaling is markedly upregulated in patients with invasive glioblastoma (GBM) after the administration of bevaciz …
Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma.
Goldlust SA, Nabors LB, Hsu S, Mohile N, Duic PJ, Benkers T, Singer S, Rao M, Cappello L, Silberman SL, Farmer G. Goldlust SA, et al. Neurooncol Adv. 2024 Jan 18;6(1):vdae009. doi: 10.1093/noajnl/vdae009. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38327681 Free PMC article.
BACKGROUND: Recurrent glioblastoma (rGBM) has limited treatment options. This phase 1 protocol was designed to study the safety and preliminary efficacy of TPI 287, a central nervous system penetrant microtubule stabilizer, in combination with bevacizumab …
BACKGROUND: Recurrent glioblastoma (rGBM) has limited treatment options. This phase 1 protocol was designed to study th …
Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
Fleischmann DF, Unterrainer M, Corradini S, Rottler M, Förster S, la Fougère C, Siepmann T, Schwaiger M, Bartenstein P, Belka C, Albert NL, Niyazi M. Fleischmann DF, et al. PLoS One. 2019 Jul 24;14(7):e0216111. doi: 10.1371/journal.pone.0216111. eCollection 2019. PLoS One. 2019. PMID: 31339892 Free PMC article. Clinical Trial.
The benefit of this technique for planning of re-irradiation (re-RT) treatment is unkown yet. Imaging data from a phase 1 trial of re-RT for recurrent glioma was analysed to assess whether planning target volumes and treatment margins in glioma re-RT c …
The benefit of this technique for planning of re-irradiation (re-RT) treatment is unkown yet. Imaging data from a phase 1 tria …
16 results